Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00153543 · ClinicalTrials.gov registry record · Phase 1
Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders
A Phase 1 study, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT00153543 is a Phase 1 study that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 86 participants.
The verdict
NCT00153543, a Phase 1 study, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
To test the hypothesis that immune responses to 23-valent pneumococcal polysaccharide vaccine (PPV-23) could be improved in Alaska Native elders by immune priming with 7-valent pneumococcal conjugate vaccine (PCV-7), we assessed post-vaccination immune responses among Natives aged 55 years and older who were randomized into three arms: (1) one dose of PPV-23 according to current state and ACIP recommendations; (2) one dose of PCV-7 followed two months later with a dose of PPV-23; and (3) one dose of PCV-7 followed six months later with a dose of PPV-23.
Interventions
- BIOLOGICAL PCV7 + PPV23, 2 months
- BIOLOGICAL PCV7 + PPV23, 6 months
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2002-05 |
| Est. Completion | 2003-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00153543
The ClinicalTrials.gov registry entry for NCT00153543 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PCV7 + PPV23, 2 months is the first listed.
NCT00153543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00153543 about?
NCT00153543 is a clinical study titled "Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders". To test the hypothesis that immune responses to 23-valent pneumococcal polysaccharide vaccine (PPV-23) could be improved in Alaska Native elders by immune priming with 7-valent pneumococcal conjugate vaccine (PCV-7), we assessed post-vaccination immune responses among Natives aged 55 years and older...
What is the current status of trial NCT00153543?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2002-05. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00153543?
The interventions under investigation include: PCV7 + PPV23, 2 months (BIOLOGICAL), PCV7 + PPV23, 6 months (BIOLOGICAL).
Who is sponsoring clinical trial NCT00153543?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.